Anavex Life Sciences Corp (AVXL)

[falconer66a]

The MOA Not Questioned

Grimmer was careful in his answers but he is definitely excited about Anavex's drug platform and it's potential ability to work on many CNS diseases.

Here is a central consideration of the comments of both Dr. Grimmer and those of other competent science professionals.

Success for Anavex and blarcamesine require that the drug actually works; is able to safely produce favorable clinical outcomes. And that depends on the viabiility, success of the drug's mechanism(s) of action (MOAs). If the drug can't actually restore or modulate normal cell physiology, clinical trials results are irrelevant. Of course, if the drug's MOA fails, treated cells remain diseased. There is no story to begin with.

Did the good doctor express any concerns that blarcamesine's MOA is flawed; that it can't actually produce the restored homeostatic conditions of non-pathologic cells? Of course not. No one any longer is questioning the MOAs of blarcamesine. They question only two things: poorly presented clinical results, and objections to corporate management.

Simply, the science and outcomes of sigma-1 receptor activation by blarcamesine are no longer in question. The drug actually works. When final clinical results are released, showing treatment successes for Rett, Alzheimer's, and Parkinson's disease dementia, CNS medicine enters a new era. Those of us with AVXL positions will be delighted (and, well, rich).